deepmirror saw a perspective on benchmark to clinical impact from A Nature Reviews Drug Discovery.
Public source
Publisher name
Public post
Our August newsletter is live! Catch up on the latest updates and insights for AI-powered drug hunters: 💻 Product updates - Redesigned side navigation - Ligand strain c…
Company
deepmirror
The foundation model for drug design
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 11–50 employees
About deepmirror
deepmirror is building the foundation model for drug design. AI for drug design is limited by sparse and fragmented data, but our AI-native infrastructure empowers chemistry teams to better harness their data to progress programs faster, with fewer dead ends. With each project, the data sets grow and the model improves, generating even greater outcomes. We are based in London and already trusted by 100+ organisations across the globe. For more information, visit http://deepmirror.ai
See moreLatest activity
Latest activity from deepmirror
8 signals
Products & Services
deepmirror updated its website and app to reflect its stellar ambitions and new look
Products & Services
deepmirror saw OpenADMET open a community blind challenge on CYP inhibition.
Products & Services
deepmirror launched additional product updates for its AI-powered drug hunting product.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Insilico Medicine
Insilico Medicine released new SOTA+ drug discovery models for drug safety and metabolism prediction, including InsilicoMMAI-Chem-ADMET, which reaches SOTA+ performance on 7 ADMET tasks.
Research & Knowledge
Biocytogen
Biocytogen published a new Nature Biotechnology study reporting AIntibody, a prospective, blinded benchmark testing 511 AI-designed or AI-selected antibodies from 29 organizations with every submission experimentally evaluated for affinity and developability.
Research & Knowledge
RoukenBio
RoukenBio published a study in Nature Biotechnology by M Frank Erasmus et al. regarding artificial intelligence in silico affinity maturation and developable designs.
Research & Knowledge
Apheris
Apheris released OpenBind-0, an open co-folding model that ships with 717 ligand-bound structures from fragment-to-hit campaigns on three real discovery targets.
Research & Knowledge
RECEPTOR.AI